Melanoma treatment
Search documents
Replimune co-founder calls FDA rejection of melanoma drug ‘unfair’
CNBC Television· 2026-04-13 15:46
joining us in a CNBC exclusive. This rep's executive chairman and co-founder, Philip Ashley Spark. Of course, uh I guess we'll start start off.Nice to have you here, by the way. Tough day for you guys. Um what do you do now other than sort of speaking publicly about I guess what you felt was a an approval process that uh was what unfair.>> Yes. Um I should I start by explaining why we think it was unfair. >> Sure.Why don't I start with a question of >> why was this approval process you by the way we should ...